FOR IMMEDIATE RELEASE

Contact:
Lisa Romero
Communications & Strategic Outreach Manager
520-547-3440
lromoerc@cpath.org
www.c-path.org

CRITICAL PATH INSTITUTE GATHERS CROSS-SECTOR INNOVATORS AT GLOBAL CONFERENCE ON DRUG DEVELOPMENT
Focus on innovative tools that accelerate the translation of science into therapies

Silver Spring, Maryland, December 1, 2011 – Hundreds of leaders from cross-sector arenas in government, academia, the biotechnology and pharmaceutical industry, and patient advocacy organizations gathered over the past two days at Critical Path Institute’s Creating Consensus Science: Tools and Tactics for Next-Gen Drug Development conference to articulate a common commitment to the future of global collaborative efforts that develop innovative tools to accelerate medical product development.

Critical Path Institute (C-Path), with the support of co-sponsors, the Clinical Data Interchange Standards Consortium (CDISC), and the U.S. Food and Drug Administration (FDA), led the two-day conference which featured six panels focused on next-gen drug development tools and tactics including data standards and pooled clinical trial databases, biomarkers, patient-reported outcomes, and disease progression models. Additional panels focused on defining and coordinating the next stages of global partnerships to accelerate the development of medical products.

Developing one efficacious medical therapy can take more than 12 years and $1 billion in laboratory research and human testing, and 95% of new drugs still fail during development. C-Path and CDISC have demonstrated that public/private partnerships focused on non-competitive consensus science have the capacity to provide new tools so that drug developers can speed important new medicines from discovery to patients more quickly.

Conference keynote speakers were Dr. Margaret Hamburg, Commissioner, FDA, and Dr. Kathy Hudson, Deputy Director for Science, Outreach, and Policy, National Institutes of Health (NIH). Other session participants included Dr. Janet Woodcock, FDA, Dr. Michel Goldman, Innovative Medicines Initiative, John Castellani, PhRMA, Myrl Weinberg, National Health Council, Dr. Jan Gheuens, Bill & Melinda Gates Foundation, Dr. ShaAvhree Buckman-Garner, FDA, Dr. Lynn Hudson, C-Path, Dr. Rebecca Kush, CDISC, Dr. Alberto Gutierrez, FDA, Dr. John Orloff, Novartis, Dr. Timothy Cote, National Organization for Rare Disorders, Dr. Chris Austin, NIH, and over 30 other key leaders committed to finding more efficient ways to speed safe, effective medicines to patients.

For a complete list of speakers and the program agenda, please click here.

###

ABOUT CRITICAL PATH INSTITUTE (C-PATH): An independent, non-profit organization established in 2005 with public and private philanthropic support from the Southern Arizona community, Science Foundation Arizona (SFAz), and the U.S. Food and Drug Administration (FDA), C-Path is committed to improving health and saving lives by accelerating the development of safe, effective medicines. An international leader in forming
collaborations around this mission, C-Path has established global, public-private partnerships that currently include over 1,000 scientists from government regulatory agencies, academia, patient advocacy organizations, and thirty five major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona, with offices in Phoenix, Arizona, and Rockville, Maryland. For more information, visit www.c-path.org and follow us on Facebook. Click here to view a video showing why the work of C-Path is essential.

*The C-Path Vision: Creating collaborations that advance scientific innovations to improve human health and save lives by accelerating the development of safe, effective medicines.*